SARASOTA, Florida, Oct. 21, 2015 /PRNewswire/ -- Rock Creek
Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug
development company which is focused on the application of its lead
compound to treat chronic inflammatory conditions, announced today
that the Company will be presenting at BIO-Europe 2015 on
Tuesday, November 3 at 11:00AM at The International Congress Center in
Munich, Germany.
Logo -
http://photos.prnewswire.com/prnh/20150617/223737LOGO
Michael Mullan, MBBS, PhD,
Chairman and CEO of Rock Creek Pharmaceuticals, will present
clinical data associated with the Company's ongoing drug
development initiatives, as well as an update to the company's
corporate and regulatory strategy.
About BIO-Europe 2015
The 21st annual BIO-Europe is Europe's largest partnering conference serving
the global biotechnology industry. Delegates from all parts of the
biotechnology value chain come to BIO-Europe to quickly identify,
engage and enter into strategic relationships that drive their
businesses successfully forward. Investment and collaboration
opportunities developed in prior BIO-Europe conferences have
produced many highly successful business partnerships. This year´s
BIO-Europe partnering event will again draw over 3,000 industry
attendees from nearly 60 countries, representing more than 1,800
companies for three days of high level networking.
BIO-Europe is organized by the EBD Group, the leading partnering
firm for the global biotechnology industry, in alliance with the
Biotechnology Industry Organization (BIO). For more information and
online registration please visit the conference website at
www.ebdgroup.com/bioeurope
About Anatabine Citrate:
Rock Creek Pharmaceuticals' compound is a small molecule,
cholinergic agonist which exhibits anti-inflammatory
pharmacological characteristics, distinct from other
anti-inflammatory drugs available such as biologics, steroids and
non-steroidal anti-inflammatories. The Company has sponsored
extensive pre-clinical (in vitro and in vivo) studies resulting in
peer reviewed and published scientific journal articles, covering
models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune
Thyroiditis. All these studies demonstrated the anti-inflammatory
effects of the Company's compound. In addition, the Company's
compilation of human exposure, safety and tolerability data, has
provided important insights for ongoing clinical and regulatory
pharmaceutical development.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. is an emerging drug development
company focused on the discovery, development and commercialization
of new drugs, formulations and compounds that provide therapies for
chronic and acute inflammatory diseases.
For more information, visit:
http://www.rockcreekpharmaceuticals.com
Forward Looking Statements:
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, failure to obtain sufficient capital resources to fund
our development program and operations, results of clinical trials
and/or other studies, the challenges inherent in new product
development initiatives, including the continued development and
approval of anti-inflammatory drug candidates, the effect of any
competitive products, our ability to license and protect our
intellectual property, our significant payables, our ability to
raise additional capital in the future that is necessary to
maintain our business, changes in government policy and/or
regulation, potential litigation by or against us, any governmental
review of our products or practices, pending litigation matters, as
well as other risks discussed from time to time in our filings with
the Securities and Exchange Commission, including, without
limitation, our annual report on Form 10-K for the fiscal year
ended December 31, 2014 filed on
March 12, 2015. We undertake no duty
to update any forward-looking statement or any information
contained in this press release or in other public disclosures at
any time.
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy & Development
Rock Creek Pharmaceuticals
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
Direct: +1-941-251-0488
tjenkins@rockcreekpharmaceuticals.com